NIK and IKK inhibitors may be promising agents in T-cell lymphomas with an activated NFKB pathway, but further studies and clinical trials are needed to evaluate the real potential of these agents in single and combined usage. This evidence concerns the gene NFKB1 and T-cell non-Hodgkin lymphoma.